Colleen A. Lawton, MD, FACR, FASTRO

Publications

• Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.

  (Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, Horwitz EM, Yamoah K, Jones CU, Michalski JM, Lee WR, Pisansky TM, Rabinovitch R, Rotman M, Pryzant RM, Kim HE, Thomas CR Jr, Shipley WU, Sandler HM.) Lancet Oncol. 2018 Nov;19(11):1504-1515.

• Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities.

  (Xiao C, Moughan J, Movsas B, Konski AA, Hanks GE, Cox JD, Roach M 3rd, Zeitzer KL, Lawton CA, Peters CA, Rosenthal SA, Hsu IJ, Horwitz EM, Mishra MV, Michalski JM, Parliament MB, D'Souza DP, Pugh SL, Bruner DW.) Adv Radiat Oncol. 2018 Jul-Sep;3(3):405-411.

• Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer.

  (Lukka HR, Pugh SL, Bruner DW, Bahary JP, Lawton CAF, Efstathiou JA, Kudchadker RJ, Ponsky LE, Seaward SA, Dayes IS, Gopaul DD, Michalski JM, Delouya G, Kaplan ID, Horwitz EM, Roach M 3rd, Pinover WH, Beyer DC, Amanie JO, Sandler HM, Kachnic LA.) Int J Radiat Oncol Biol Phys. 2018 10 01;102(2):287-295.

• Prostate Cancer: Improving the Flow of Research.

  (Lawton CAF.) Radiology. 2018 04;287(1):5-9.

• Magnetic Resonance Imaging-Guided Adaptive Radiation Therapy: A Game Changer for Prostate Treatment?

  (Pathmanathan AU, van As NJ, Kerkmeijer LGW, Christodouleas J, Lawton CAF, Vesprini D, van der Heide UA, Frank SJ, Nill S, Oelfke U, van Herk M, Li XA, Mittauer K, Ritter M, Choudhury A, Tree AC.) Int J Radiat Oncol Biol Phys. 2018 Feb 01;100(2):361-373.

• Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.

  (Lawton CAF, Lin X, Hanks GE, Lepor H, Grignon DJ, Brereton HD, Bedi M, Rosenthal SA, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Kim H, Parliament MB, Rabinovitch R, Roach M 3rd, Kwok Y, Dignam JJ, Sandler HM.) Int J Radiat Oncol Biol Phys. 2017 06 01;98(2):296-303.

• Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.

  (Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CAF, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM.) Cancer. 2017 Jul 01;123(13):2489-2496.

• Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.

  (Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM, NRG Oncology RTOG.) N Engl J Med. 2017 02 02;376(5):417-428.

• Biomarkers of Outcome in Patients With Localized Prostate Cancer Treated With Radiotherapy.

  (Hall WA, Lawton CA, Jani AB, Pollack A, Feng FY.) Semin Radiat Oncol. 2017 01;27(1):11-20.

• A Hybrid Adaptive Replanning Approach for Prostate Stereotactic Body Radiation Therapy.

  (Ates O, Ahunbay EE, Lawton CA, Li A.) Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):E668-E669.

• Quality of life outcomes from a dose-per-fraction escalation trial of hypofractionation in prostate cancer.

  (Brower JV, Forman JD, Kupelian PA, Petereit DG, Gondi V, Lawton CA, Anger N, Saha S, Chappell R, Ritter MA.) Radiother Oncol. 2016 Jan;118(1):99-104.

• Watchful Waiting-Active Surveillance in Low-Risk Prostate Cancer.

  (Haffty BG, Lawton CA, Sandler H.) JAMA Oncol. 2015 Aug;1(5):688-9.